Abstract
Binding of biologically important molecules with plasma proteins highly influence its availability, distribution, and metabolism, and thus has great significance in determining its therapeutic efficiency. Hence, studying its interaction with plasma proteins is prime and inevitable. Herein, we have investigated the molecular interaction of Pexidartinib, a novel, primitive and highly selective therapeutical agent against CSF-1R overexpression, with human serum albumin (HSA) and bovine serum albumin (BSA) using various spectroscopic methods, docking and simulations. The intrinsic fluorescence of the proteins considerably quenched on PEX addition accompanied by a slight blue shift. The complex formation between PEX and BSA/HSA induced some alterations in the molecular milieu of the tryptophan residues. The active binding locus was found to be within the hydrophobic cavity of Sudlow site I of both BSA and HSA. The binding dynamics suggest the interplay of hydrogen bonding and hydrophobic interactions in complex stabilisation. MD simulations provides valuable insights into the dynamic facets of the molecular recognition processes involved and governs the stability factor of protein post ligand complexation.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.